Compare Rigetti Computing Inc (RGTI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rigetti Computing Inc vs Recursion Pharmaceuticals Inc — how do they compare? Rigetti Computing Inc trades at $15.19 (market cap $5.08B), while Recursion Pharmaceuticals Inc trades at $3 (market cap $1.63B). The key difference: Rigetti Computing Inc is far larger — about 3.1× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| RGTI | RXRX | |
|---|---|---|
Market Cap | $5.08B | $1.63B |
Sector | Technology | Health |
52-Week High | $56.34 | $6.79 |
52-Week Low | $12.90 | $2.84 |
Enterprise Value | $4.67B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rigetti Computing (RGTI) trades at $14.25, up 0.99% on the day, while showing bearish technical signals with 17 sell indicators versus 5 buy signals. The company maintains strong analyst support with 85.7% buy ratings and a $32.67 consensus price target, despite posting significant losses (-$216.21M net income) and negative margins. Recent news highlights Rigetti's $569M cash position and government contracts supporting its quantum computing roadmap.
RGTI offers substantial upside potential based on analyst targets but carries high risk due to persistent losses and negative profitability metrics. The stock's investment thesis hinges on successful quantum technology commercialization, with current valuation reflecting speculative growth expectations rather than fundamental performance.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
